Healthcare, Pharma & Life Sciences

Natural Field Launches NF TriSolve SleepRestore Complex

Image
Natural Field Launches NF TriSolve SleepRestore Complex

Shanghai – September 12, 2026 -- Natural Field has expanded its NF TriSolve® branded nutraceutical solution platform into the sleep wellness category with the launch of NF TriSolve® SleepRestore Complex, targeting global nutrition brands seeking differentiated formulations.

Natural Field enters sleep wellness market with coordinated multi-ingredient formulation

The new SleepRestore Complex combines multiple functional components into a single coordinated concept designed specifically for sleep-focused nutraceutical applications. The launch marks Natural Field's push beyond its existing categories into the growing sleep wellness segment, following a solution-oriented innovation model rather than single-ingredient development.

Carboxymethylcellulose Calcium Market to Hit $0.09B by 2036

Image
Carboxymethylcellulose Calcium Market to Hit $0.09B by 2036

Delray Beach – – September 12, 2026 -- The global carboxymethylcellulose calcium market will grow from $0.06 billion in 2026 to $0.09 billion by 2036, expanding at a compound annual growth rate of 4.8%, according to a new MarketsandMarkets forecast.

Asia Pacific emerges as the fastest-growing regional market through 2036

Asia Pacific is projected to post the highest CAGR of 5.2% over the forecast period, driven by expanding pharmaceutical manufacturing in China and India, rising generic drug output, and growing contract manufacturing activity. Well-established supply chains in both countries are reinforcing cost-efficient production and rising domestic consumption of cellulose-based excipients.

IVI RMA North America Adds Illume Fertility, Expands Northeast Network

Hartford, Conn. – September 12, 2026 -- IVI RMA North America has partnered with Illume Fertility, adding the Connecticut-based provider's five clinics across Connecticut and New York to its regional network. The deal extends IVI RMA's existing Northeast footprint, which includes operations in Boston and New Jersey, into a more integrated multi-state fertility care corridor.

Illume brings nine board-certified specialists into the IVI RMA fold

Illume Fertility's clinical team consists of nine fertility specialists, each board-certified in reproductive endocrinology and infertility as well as obstetrics and gynecology. The physicians hold fellowship training in fertility treatment, hormone regulation, and assisted conception.

INBI Launches in Israel, Names Anat Cohen-Dayag CEO of Core Unit

Image
INBI Launches in Israel, Names Anat Cohen-Dayag CEO of Core Unit

Tel Aviv – – September 12, 2026 -- The Israel National Biotech Innovation Center (INBI) officially launched operations, uniting 15 of Israel's top universities, research institutions and healthcare organizations under a single translational platform for the first time.

Anat Cohen-Dayag Takes Helm of INBI Core

Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen and formerly its President and CEO for 15 years, has been appointed Chief Executive Officer of INBI Core Ltd., the wholly owned operational subsidiary of INBI. Samuel Moed, former Senior Vice President of Corporate Strategy at Bristol Myers Squibb, will chair both INBI and INBI Core.

REGENXBIO to Present at Baird, Morgan Stanley Healthcare Conferences

Image
REGENXBIO to Present at Baird, Morgan Stanley Healthcare Conferences

Rockville, Maryland – September 12, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) will hold fireside chats at two major investor healthcare conferences in New York this month.

REGENXBIO confirms back-to-back fireside chats on September 15 and 16

The gene therapy company will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, followed by the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Both sessions will take place in New York, NY.

Unicycive Stock Plunges 39% as FDA Rejects Kidney Drug Again

Image
Unicycive Stock Plunges 39% as FDA Rejects Kidney Drug Again

San Diego – September 12, 2026 -- Shareholder rights firm Robbins LLP has filed a class action against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who purchased the biotech's securities between September 12, 2026 and September 12, 2026, after the FDA rejected the company's kidney disease drug for a second time over unresolved manufacturing deficiencies.

FDA Issues Second Rejection Citing Identical Manufacturing Flaws

On September 12, 2026, before markets opened, Unicycive disclosed that the FDA had issued a Complete Response Letter for its resubmitted New Drug Application for oxylanthanum carbonate (OLC), identifying the "same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025." Shares fell $3.01, or 39.1%, to close at $4.69 on unusually heavy trading volume that day.

Ascletis Launches U.S. Phase I Trial for Oral Obesity Drug ASC36

Image
Ascletis Launches U.S. Phase I Trial for Oral Obesity Drug ASC36

Hong Kong – September 12, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) has initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, after securing Investigational New Drug clearance from the FDA.

Trial enrolls 86 participants to test safety and dosing

The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of ASC36 across single and multiple ascending oral doses in 86 participants with obesity (BMI ≥ 30.0 kg/m2) or overweight status (BMI ≥ 27.0 kg/m2). This marks the fourth Phase I peptide study Ascletis has launched in 2026.

Modern Micro Endodontics Opens Ninth NJ Office via Acquisition

Image
Modern Micro Endodontics Opens Ninth NJ Office via Acquisition

Englewood Cliffs, N.J. – September 12, 2026 -- Modern Micro Endodontics has opened its ninth New Jersey location at 617 E. Palisades Ave, Suite 3 in Englewood Cliffs, acquiring the practice of longtime local endodontist Dr. Anthony Fasciano, DMD.

Ownership transition adds Bergen County to a nine-office New Jersey network

The deal extends Modern Micro Endodontics' specialty footprint into Bergen County, adding root canal therapy, surgical endodontics, and same-day emergency treatment for area patients and referring dentists. Dr. Fasciano, who led the Englewood Cliffs practice for many years, selected Modern Micro Endodontics as his successor and will remain with the office temporarily to support the handoff; longtime staff will continue in their roles.

Parakeet Health, Qualderm Deploy AI to Cut Dermatology Wait Times

Image
Parakeet Health, Qualderm Deploy AI to Cut Dermatology Wait Times

San Francisco and Nashville – September 12, 2026 -- Parakeet Health and Qualderm have launched an AI-driven scheduling collaboration to reconnect dermatology patients across a network of nearly 160 practices in 17 states, as appointment wait times climb nationwide.

Dermatology wait times rise 6% since 2022, hitting 36.5 days on average

A recent study cited by the companies found patients in 15 major U.S. metropolitan areas now wait an average of 36.5 days for a dermatology appointment, up 6% since 2022. Qualderm, a management services organization supporting medical, surgical and cosmetic dermatology, skin cancer care, and plastic surgery practices, cited this access gap as the driver behind the partnership.

GOBEL Launches Gratify, AI Platform Fusing EMR and CRM Data for Donor Prospecting

Image
GOBEL Launches Gratify, AI Platform Fusing EMR and CRM Data for Donor Prospecting

Tampa, Fla. – September 12, 2026 -- GOBEL has launched Gratify, a grateful patient intelligence platform that fuses electronic medical record (EMR) and constituent relationship management (CRM) data to help hospitals and health system foundations identify and prioritize donor prospects.

Gratify merges clinical and philanthropic data into a single Prospect Intelligence Profile

The platform combines clinical signals from EMR systems with giving history and engagement data from CRM systems, using GOBEL's proprietary AI-powered predictive models. Unlike general nonprofit benchmarking tools, these models were trained specifically on combined clinical and philanthropic records for healthcare philanthropy applications.